AxoProtego Therapeutics, LLC is a preclinical-phase therapeutics company focused on neuroprotection via modulation of heat shock protein 90 (HSP90) chaperone activity on an RNA splicing protein with the compound ethoxyquin and its analog. Ethoxyquin (EQ) is a quinoline-based, small molecule antioxidant. The Company has completed extensive preclinical and animal validation of ethoxyquin and its novel analogs ethoxyquin-6 (EQ-6)...
AxoProtego Therapeutics, LLC is a preclinical-phase therapeutics company focused on neuroprotection via modulation of heat shock protein 90 (HSP90) chaperone activity on an RNA splicing protein with the compound ethoxyquin and its analog. Ethoxyquin (EQ) is a quinoline-based, small molecule antioxidant. The Company has completed extensive preclinical and animal validation of ethoxyquin and its novel analogs ethoxyquin-6 (EQ-6) including: (1) in vitro studies to determine protection from axon degeneration due to different chemotherapy drugs; (2) efficacy studies in animal models of Chemotherapy Induced Peripheral Neuropathy (CIPN), etc.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.